| Leukemia(I) | CTCL(I) | CTCL(II) | Head & Neck vs. Lung tumors (I) | Head & Neck vs. Lung tumors (II) | Prostate | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | #c | #g | ACC | #c | #g | ACC | #c | #g | ACC | #c | #g | ACC | #c | #g | ACC | #c | #g | ACC |
SVM- | 2 | 12 | 99% | 2 | 8 | 100% | 2 | 8 | 91% | 2 | 8 | 100% | 2 | 9 | 100% | 2 | 8 | 87% |
RCE | 3 | 32 | 98% | 9 | 32 | 100% | 9 | 34 | 96% | 8 | 32 | 100% | 6 | 32 | 100% | 11 | 36 | 95% |
 | 28 | 100 | 97% | 32 | 101 | 100% | 28 | 104 | 96% | 28 | 103 | 100% | 25 | 103 | 100% | 32 | 100 | 93% |
SVM-RFE | Â | 11 | 96% | Â | 9 | 89% | Â | 8 | 84% | Â | 8 | 92% | Â | 8 | 98% | Â | 8 | 93% |
 |  | 32 | 96% |  | 32 | 94% |  | 32 | 85% |  | 32 | 90% |  | 32 | 98% |  | 36 | 95% |
 |  | 102 | 97% |  | 102 | 100% |  | 102 | 87% |  | 102 | 90% |  | 102 | 98% |  | 102 | 94% |
PDA-RFE | Â | 8 | 96% | Â | 8 | 92% | Â | 8 | 83% | Â | 8 | 89% | Â | 8 | 70% | Â | 8 | 94% |
 |  | 32 | 96% |  | 32 | 92% |  | 33 | 81% |  | 31 | 96% |  | 32 | 98% |  | 32 | 94% |
 |  | 104 | 96% |  | 104 | 95% |  | 108 | 79% |  | 109 | 96% |  | 102 | 98% |  | 104 | 90% |